Mesoblast revenue reaches $36 million from Ryoncil
- Mesoblast reported preliminary Ryoncil net revenue of $36 million for the June 2026 quarter.
- The company ended FY2026 with $103 million in cash after refinancing debt obligations.
- Mesoblast advanced clinical trials for Ryoncil, rexlemestrocel-L and its CAR-MSC platform.
Mesoblast (NASDAQ:MESO) reported preliminary Ryoncil® net revenue of $36 million for the June 2026 quarter, bringing first-year post-FDA approval revenue to $115 million.
The company generated $66.5 million in Ryoncil revenue during the second half of FY2026, while net operating cash spend for the full year was $43.8 million compared with $13.4 million in the second half.
Mesoblast ended FY2026 with $103 million in cash after drawing $50 million from a five-year facility to repay all maturing debt, while continuing clinical development programs for Ryoncil and rexlemestrocel-L.
The company is advancing a registrational trial to expand Ryoncil’s label to adults with steroid-refractory acute graft-versus-host disease.
Mesoblast received FDA IND clearance for a registrational trial of Ryoncil in ambulatory children with Duchenne muscular dystrophy and completed enrollment of at least 300 patients in a Phase 3 trial of rexlemestrocel-L for chronic low back pain.
The company also obtained a BLA filing number and requested modular review for rexlemestrocel-L in preventing LVAD-associated gastrointestinal bleeding, while licensing a CAR-MSC platform targeting inflammatory bowel disease and B cell autoimmune conditions.
